Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centella asiatica in elderly with mild cognitive impairment
NCT03937908Phase 1Terminated
- Sponsor
- Oregon Health & Science University
- Start
- Oct 2019
- Primary completion
- Dec 2020
- Modality
- PE (Plant extract)
- Countries
- 1
01
Overview
Phase 1, open-label trial of centella asiatica in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD), sponsored by Oregon Health & Science University. Started Oct 2019; status: terminated.
02
Drugs
centella asiatica
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03937908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937908.